Vanda Pharmaceuticals Inc. (VNDA) shareholders
Close on Nov 18, 2026Market cap $226.76MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 4,699,280 | 8.10% | 13G (passive) amendment | Jan 31, 2025 |
| Israel A. Englander Joint filing with Millennium Management LLC (7.00%), Millennium Group Management LLC (7.00%) | 4,260,038 | 7.00% | 13G (passive) amendment | Sep 30, 2026 |
| Renaissance Technologies LLC Joint filing with Renaissance Technologies Holdings Corporation (6.40%) | 3,681,125 | 6.40% | 13G (passive) amendment | Dec 29, 2023 |
| BlackRock Portfolio Management LLC | 3,587,013 | 5.90% | 13G (passive) | Sep 30, 2026 |
| AQR Capital Management, LLC Joint filing with AQR Capital Management Holdings, LLC (5.82%) | 3,497,695 | 5.82% | 13G (passive) | Jun 30, 2026 |
| Millennium Management LLC Joint filing with Millennium Group Management LLC (5.60%), Israel A. Englander (5.60%) | 3,376,401 | 5.60% | 13G (passive) | Aug 17, 2026 |
| Millennium Group Management LLC Joint filing with Millennium Management LLC (5.30%), Israel A. Englander (5.30%) | 3,120,339 | 5.30% | 13G (passive) | Jun 27, 2025 |
| State Street Corporation | 3,010,531 | 5.00% | 13G (passive) | Sep 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of VNDA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 7,653,737 | 12.66% | $46.84M | +377,749 | 0.00% |
| State Street Corp | 3,516,405 | 5.82% | $21.52M | +500,843 | 0.00% |
| Aqr Capital Management LLC | 3,497,695 | 5.78% | $21.41M | +1,894,119 | 0.01% |
| Renaissance Technologies LLC | 3,441,361 | 5.69% | $21.06M | −318,198 | 0.03% |
| Vanguard Capital Management LLC | 2,524,040 | 4.17% | $15.45M | +42,549 | 0.00% |
| AIGH Capital Management LLC | 2,044,169 | 3.38% | $12.51M | −705,831 | 0.79% |
| Acadian Asset Management LLC | 1,918,063 | 3.17% | $11.73M | +122,471 | 0.01% |
| Dimensional Fund Advisors LP | 1,727,349 | 2.86% | $10.57M | −44,244 | 0.00% |
| Millennium Management LLC | 1,602,813 | 2.65% | $9.81M | −278,188 | 0.00% |
| Geode Capital Management, LLC | 1,483,787 | 2.45% | $9.08M | +40,822 | 0.00% |
| Two Sigma Investments, LP | 1,349,072 | 2.23% | $8.26M | −49,129 | 0.01% |
| Marshall Wace, Llp | 1,225,996 | 2.03% | $7.50M | +629,994 | 0.01% |
| Jacobs Levy Equity Management, Inc | 1,213,326 | 2.01% | $7.43M | +44,645 | 0.03% |
| Krensavage Asset Management, LLC | 1,180,388 | 1.95% | $7.22M | – | 2.74% |
| Vanguard Portfolio Management LLC | 1,131,034 | 1.87% | $6.92M | +116,512 | 0.00% |
| Goldman Sachs Group Inc | 1,036,260 | 1.71% | $6.34M | +198,027 | 0.00% |
| Citadel Advisors LLC | 758,302 | 1.25% | $4.64M | +124,948 | 0.00% |
| Qube Research & Technologies Ltd | 729,212 | 1.21% | $4.46M | New | 0.00% |
| Federated Hermes, Inc. | 714,278 | 1.18% | $4.37M | +138,889 | 0.01% |
| Charles Schwab Investment Management Inc | 646,256 | 1.07% | $3.96M | +94,486 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 172 | 50M | 82.2% | 28 / 68 | 55 / 25 | 8M | 4M |
| Q1 2026 | 171 | 46M | 76.4% | 50 / 62 | 40 / 29 | 14M | 6M |
| Q4 2025 | 153 | 42M | 69.4% | 28 / 40 | 64 / 23 | 6M | 9M |
| Q3 2025 | 150 | 45M | 74.6% | 24 / 50 | 51 / 13 | 4M | 4M |
| Q2 2025 | 139 | 45M | 74.5% | 21 / 47 | 46 / 28 | 5M | 4M |
| Q1 2025 | 146 | 44M | 72.8% | 20 / 46 | 53 / 18 | 4M | 4M |
| Q4 2024 | 146 | 43M | 71.5% | 21 / 53 | 44 / 25 | 4M | 5M |
| Q3 2024 | 152 | 44M | 73.0% | 26 / 46 | 53 / 20 | 12M | 5M |
| Q2 2024 | 148 | 45M | 74.9% | 38 / 43 | 47 / 34 | 8M | 14M |
| Q1 2024 | 144 | 52M | 85.4% | 19 / 46 | 59 / 32 | 7M | 10M |
| Q4 2023 | 157 | 54M | 89.2% | 26 / 54 | 55 / 47 | 10M | 9M |
| Q3 2023 | 179 | 52M | 86.5% | 28 / 64 | 66 / 35 | 12M | 15M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
182 funds held VNDA in Q2 2026, 60% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of VNDA | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,291,699 | 3.79% | $14.03M | 0.13% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 1,761,840 | 2.91% | $10.78M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,403,798 | 2.32% | $8.59M | 0.01% | Jun 30, 2026 |
| Federated Hermes MDT Small Cap Core Fund | 1,080,147 | 1.79% | $5.51M | 0.25% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 703,761 | 1.16% | $4.31M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 585,865 | 0.97% | $2.99M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 516,485 | 0.85% | $3.16M | 0.02% | Jun 30, 2026 |
| BlackRock Advantage Small Cap Core Fund | 489,961 | 0.81% | $3.16M | 0.06% | May 29, 2026 |
| iShares Biotechnology ETF | 402,512 | 0.67% | $2.46M | 0.03% | Jun 30, 2026 |
| U.S. Small Cap Value Portfolio | 333,667 | 0.55% | $1.70M | 0.01% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 310,605 | 0.51% | $2.00M | 0.00% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 286,177 | 0.47% | $1.85M | 0.01% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 285,556 | 0.47% | $1.84M | 0.01% | May 31, 2026 |
| U.S. Small Cap Portfolio | 268,928 | 0.44% | $1.37M | 0.01% | Jul 31, 2026 |
| Vanguard U.S. Momentum Factor ETF | 256,365 | 0.42% | $1.65M | 0.09% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Mihael Hristos Polymeropoulos | President and CEO, Director | 2,704,496 | 4.47% | Mar 4, 2026 |
| Daniel Patrick McGuire | SVP, GC and Secretary | 109,982 | 0.18% | Jun 8, 2026 |
| Christos Vasilios Mihael Polymeropoulos | Senior VP, Medical Director | 129,791 | 0.21% | Apr 13, 2026 |
| Scott Laverne Howell | VP and Chief People Officer | 109,620 | 0.18% | Apr 13, 2026 |
| Joakim Wijkstrom | SVP, Chief Marketing Officer | 333,469 | 0.55% | Mar 4, 2026 |
| Timothy Williams | SVP & General Counsel | 377,450 | 0.62% | Mar 4, 2026 |
| Gunther Birznieks | SVP, Business Development | 494,197 | 0.82% | Mar 4, 2026 |
| Kevin Patrick Moran | SVP, CFO & Treasurer | 412,015 | 0.68% | Mar 4, 2026 |
| Charles Cliff Duncan | Director | 108,701 | 0.18% | Nov 5, 2026 |
| Richard W. Dugan | Director | 219,054 | 0.36% | Jun 8, 2026 |
| Phaedra Chrousos | Director | 164,950 | 0.27% | Jun 8, 2026 |
| Anne Sempowski Ward | Director | 160,667 | 0.27% | Jun 8, 2026 |
| Stephen Ray Mitchell | Director | 112,846 | 0.19% | Jun 8, 2026 |
| Tage Honore | Director | 135,069 | 0.22% | Jun 8, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Charles Cliff Duncan Director | Nov 5, 2026 | Buy | +5,803 | $3.80 | $22.08K | 108,701 |
| Charles Cliff Duncan Director | Nov 4, 2026 | Buy | +3,447 | $3.82 | $13.17K | 102,898 |
| Charles Cliff Duncan Director | Nov 3, 2026 | Buy | +750 | $3.80 | $2.85K | 99,451 |
| Stephen Ray Mitchell Director | Jun 4, 2026 | Award | +41,600 | – | – | 112,846 |
| Daniel Patrick McGuire SVP, GC and Secretary | Jun 4, 2026 | Award | +80,000 | – | – | 109,982 |
| Tage Honore Director | Jun 4, 2026 | Award | +41,600 | – | – | 135,069 |
| Anne Sempowski Ward Director | Jun 4, 2026 | Award | +41,600 | – | – | 160,667 |
| Richard W. Dugan Director | Jun 4, 2026 | Award | +41,600 | – | – | 219,054 |
| Charles Cliff Duncan Director | Jun 4, 2026 | Award | +41,600 | – | – | 98,701 |
| Phaedra Chrousos Director | Jun 4, 2026 | Award | +41,600 | – | – | 164,950 |
| Stephen Ray Mitchell Director | May 18, 2026 | Gift | −25,836 | – | – | 71,246 |
| Charles Cliff Duncan Director | Apr 22, 2026 | Award | +57,101 | – | – | 57,101 |
| Kevin Patrick Moran SVP, CFO & Treasurer | Mar 2, 2026 | Sale | −42,442 | $8.27 | $351.00K | 411,380 |
| Mihael Hristos Polymeropoulos President and CEO, Director | Mar 2, 2026 | Sale | −156,235 | $8.17 | $1.28M | 2,704,496 |
| Gunther Birznieks SVP, Business Development | Mar 2, 2026 | Sale | −42,431 | $8.27 | $350.90K | 494,197 |
| Timothy Williams SVP & General Counsel | Mar 2, 2026 | Sale | −42,434 | $8.27 | $350.93K | 377,450 |
| Joakim Wijkstrom SVP, Chief Marketing Officer | Mar 2, 2026 | Sale | −30,800 | $8.27 | $254.72K | 333,469 |
| Tage Honore Director | Feb 23, 2026 | Sale | −30,000 | $8.03 | $240.90K | 93,469 |
| Timothy Williams SVP & General Counsel | Feb 18, 2026 | Award | +125,000 | – | – | 419,884 |
| Mihael Hristos Polymeropoulos President and CEO, Director | Feb 18, 2026 | Award | +525,000 | – | – | 2,860,731 |
| Kevin Patrick Moran SVP, CFO & Treasurer | Feb 18, 2026 | Award | +125,000 | – | – | 453,822 |
| Gunther Birznieks SVP, Business Development | Feb 18, 2026 | Award | +125,000 | – | – | 536,628 |
| Joakim Wijkstrom SVP, Chief Marketing Officer | Feb 18, 2026 | Award | +125,000 | – | – | 364,269 |
| Mihael Hristos Polymeropoulos President and CEO, Director | Aug 7, 2025 | Buy | +10,000 | $4.15 | $41.50K | 2,335,731 |
| Stephen Ray Mitchell Director | Jun 13, 2025 | Sale | −7,000 | $4.59 | $32.13K | 97,082 |
| Anne Sempowski Ward Director | Jun 5, 2025 | Award | +59,225 | – | – | 119,067 |
| Phaedra Chrousos Director | Jun 5, 2025 | Award | +59,225 | – | – | 123,350 |
| Tage Honore Director | Jun 5, 2025 | Award | +59,225 | – | – | 123,469 |
| Stephen Ray Mitchell Director | Jun 5, 2025 | Award | +59,225 | – | – | 104,082 |
| Richard W. Dugan Director | Jun 5, 2025 | Award | +59,225 | – | – | 177,454 |
| Mihael Hristos Polymeropoulos President and CEO, Director | May 21, 2025 | Buy | +481 | $4.39 | $2.11K | 2,325,731 |
| Mihael Hristos Polymeropoulos President and CEO, Director | May 21, 2025 | Buy | +9,519 | $4.40 | $41.88K | 2,325,250 |
| Mihael Hristos Polymeropoulos President and CEO, Director | May 16, 2025 | Buy | +20,000 | $4.22 | $84.40K | 2,315,731 |
| Mihael Hristos Polymeropoulos President and CEO, Director | Mar 6, 2025 | Buy | +5,000 | $5.02 | $25.10K | 2,290,731 |
| Mihael Hristos Polymeropoulos President and CEO, Director | Mar 6, 2025 | Buy | +5,000 | $5.01 | $25.05K | 2,295,731 |
| Mihael Hristos Polymeropoulos President and CEO, Director | Mar 5, 2025 | Buy | +5,000 | $5.03 | $25.15K | 2,285,731 |
| Mihael Hristos Polymeropoulos President and CEO, Director | Mar 5, 2025 | Buy | +5,000 | $5.01 | $25.05K | 2,280,731 |
| Mihael Hristos Polymeropoulos President and CEO, Director | Mar 3, 2025 | Buy | +10,000 | $4.71 | $47.10K | 2,275,731 |
| Joakim Wijkstrom SVP, Chief Marketing Officer | Mar 1, 2025 | Tax withholding | −15,520 | $4.76 | $73.88K | 239,269 |
| Gunther Birznieks SVP, Business Development | Mar 1, 2025 | Tax withholding | −26,941 | $4.76 | $128.24K | 411,628 |
| Timothy Williams SVP & General Counsel | Mar 1, 2025 | Tax withholding | −26,941 | $4.76 | $128.24K | 294,884 |
| Kevin Patrick Moran SVP, CFO & Treasurer | Mar 1, 2025 | Tax withholding | −26,941 | $4.76 | $128.24K | 328,822 |
| Mihael Hristos Polymeropoulos President and CEO, Director | Mar 1, 2025 | Tax withholding | −95,999 | $4.76 | $456.96K | 2,265,731 |
| Mihael Hristos Polymeropoulos President and CEO, Director | Feb 28, 2025 | Buy | +10,000 | $4.76 | $47.60K | 2,361,730 |
| Mihael Hristos Polymeropoulos President and CEO, Director | Feb 27, 2025 | Buy | +10,000 | $4.76 | $47.60K | 2,351,730 |
| Mihael Hristos Polymeropoulos President and CEO, Director | Feb 26, 2025 | Buy | +5,000 | $4.78 | $23.90K | 2,341,730 |
| Mihael Hristos Polymeropoulos President and CEO, Director | Feb 26, 2025 | Buy | +5,000 | $4.75 | $23.75K | 2,336,730 |
| Mihael Hristos Polymeropoulos President and CEO, Director | Feb 25, 2025 | Buy | +10,000 | $4.46 | $44.60K | 2,331,730 |
| Kevin Patrick Moran SVP, CFO & Treasurer | Feb 21, 2025 | Buy | +2,000 | $4.39 | $8.78K | 355,763 |
| Gunther Birznieks SVP, Business Development | Feb 18, 2025 | Award | +125,000 | – | – | 438,569 |
| Joakim Wijkstrom SVP, Chief Marketing Officer | Feb 18, 2025 | Award | +125,000 | – | – | 254,789 |
| Kevin Patrick Moran SVP, CFO & Treasurer | Feb 18, 2025 | Award | +125,000 | – | – | 353,763 |
| Timothy Williams SVP & General Counsel | Feb 18, 2025 | Award | +125,000 | – | – | 321,825 |
| Mihael Hristos Polymeropoulos President and CEO, Director | Feb 18, 2025 | Award | +450,000 | – | – | 2,321,730 |
| Stephen Ray Mitchell Director | Nov 14, 2024 | Sale | −5,000 | $5.17 | $25.85K | 44,857 |
| Kevin Patrick Moran SVP, CFO & Treasurer | Jul 29, 2024 | Sale | −2,251 | $5.92 | $13.33K | 228,763 |
| Phaedra Chrousos Director | May 22, 2024 | Award | +21,887 | – | – | 64,125 |
| Richard W. Dugan Director | May 17, 2024 | Award | +20,529 | – | – | 118,229 |
| Anne Sempowski Ward Director | May 17, 2024 | Award | +20,529 | – | – | 59,842 |
| Stephen Ray Mitchell Director | May 17, 2024 | Award | +20,529 | – | – | 49,857 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Vanda Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 79,287 shares on Sep 29, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Kevin Patrick Moran SVP, CFO & Treasurer | Mar 2, 2026 | 42,442 | $350.82K | Mar 2, 2026 | Vesting/Settlement of Restricted Stock Units |
| Mihael Hristos Polymeropoulos Officer, Chairman of the Board | Mar 2, 2026 | 156,235 | $1.28M | Mar 2, 2026 | Vesting/Settlement of Restricted Stock Units |
| Joakim Wijkstrom SVP, Chief Marketing Officer | Mar 2, 2026 | 30,800 | $254.59K | Mar 2, 2026 | Vesting/Settlement of Restricted Stock Units |
| Gunther Birznieks SVP, Business Development | Mar 2, 2026 | 42,431 | $350.73K | Mar 2, 2026 | Vesting/Settlement of Restricted Stock Units |
| Timothy Williams SVP & General Counsel | Mar 2, 2026 | 42,434 | $350.76K | Mar 2, 2026 | Vesting/Settlement of Restricted Stock Units |
| Tage Honore Director | Feb 23, 2026 | 30,000 | $240.90K | Feb 23, 2026 | Vesting / Settlement of Restricted Stock Units |
| Stephen Ray Mitchell Director | Jun 13, 2025 | 7,000 | $32.16K | Jun 13, 2025 | Vesting/Settlement of Restricted Stock Units |
| Stephen Ray Mitchell Director | Nov 14, 2024 | 5,000 | $27.00K | Nov 14, 2024 | Vesting/Settlement of Restricted Stock Units |
| Kevin Patrick Moran Officer | Jul 29, 2024 | 2,251 | $13.33K | Jul 29, 2024 | Vesting/Settlement of Restricted Stock Units |
| Joakim Wijkstrom Officer | Mar 4, 2024 | 30,300 | $139.68K | Mar 4, 2024 | Vesting/Settlement of Restricted Stock Units |
| Timothy Williams Officer | Mar 4, 2024 | 32,025 | $147.64K | Mar 4, 2024 | Vesting/Settlement of Restricted Stock Units |
| Gunther Birznieks Officer | Mar 4, 2024 | 32,025 | $147.64K | Mar 4, 2024 | Vesting/Settlement of Restricted Stock Units |
| Mihael Hristos Polymeropoulos Officer, Director, Chairman of the Board | Mar 4, 2024 | 101,250 | $466.76K | Mar 4, 2024 | Vesting/Settlement of Restricted Stock Units |
| Kevin Patrick Moran Officer | Mar 4, 2024 | 27,689 | $127.65K | Mar 4, 2024 | Vesting/Settlement of Restricted Stock Units |
| Joakim Wijkstrom Officer | Aug 21, 2023 | 3,724 | $21.75K | Aug 21, 2023 | Vesting/Settlement of Restricted Stock Units |
See a number that looks wrong?